Table 3.

Selected studies evaluating radiolabeled somatostatin analogs for treatment of NETs

Study	N	Radiolabeled somatostatin analog	Response rates (PR+CR)	Symptom relief or reduction	Median overall survival
Bushnell, 2010 USA	90	90-Y-edotreotide	4%	>50%	26.9 months
Delpassand, 2008 USA	18	In-111 pentetreotide	11%	NA	13.3 months
Kwekkeboom 2008 Netherlands	310	Lu-177-octreotate	30%	NA	46 months
Forrer 2006 Switzerland	116	90-Y-DOTATOC	27%	83%	NA
Anthony 2002 USA	26	In-111 pentetreotide	8%	62%	18 months

Abbreviations: CR, complete remission; In-111, indium 111; Lu-177, leutium-177; NA, not available; PR, partial remission; 90-Y, 90-yttrium.

References: Anthony et al., 2002; Bushnell et al., 2010; Delpassand et al., 2008; Forrer et al., 2006; Kwekkeboom et al., 2008.